ArticleMetabolic brain disease2025
Mechanisms of SIRT1/SIRT3-mediated reduction of mitochondrial regeneration and inflammatory response in diabetic cerebral ischemia-reperfusion injury.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fingolimod Improves Anxiety-like Behavior and Modulates Sphingosine-1-Phosphate Receptors Gene Expression in a Diabetic Mouse Model.Biomolecules · 2025Article
- The mechanism and therapeutic potential of SIRT3 in central nervous system diseases: a review.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the specific mechanisms by which SIRT1/SIRT3 modulates the reduction of mitochondrial regeneration and the inflammatory response in cerebral ischemia-reperfusion(I/R) injury exacerbated by hyperglycemia. A streptozotocin-induced diabetic rat model was developed to simulate diabetes mellitus(DM), and embolization of the middle cerebral artery was performed to establish cerebral I/R injury. Brain damage was assessed via neurological function scores, TTC staining, HE staining and electron microscopy. SIRT1/SIRT3 mRNA levels and initial mitochondrial DNA (mtDNA) content were quantified using RT-qPCR. Proteins of SIRT1/SIRT3 and proteins associated with mitochondrial regeneration and the inflammatory response were validated by western blot analysis. The production of reactive oxygen species (ROS) and inflammatory factors was assayed by ELISA. The findings indicated a significant increase in neurological function scores across all groups experiencing diabetic cerebral I/R injury (P < 0.05). Additionally, a notable increase was observed in cerebral infarction volume (P < 0.05) and neuronal necrosis (P < 0.05) and the structure and morphology of the cells were significantly altered. the levels of SIRT1/SIRT3 were found to be significantly reduced (P < 0.05). Furthermore, the levels of PGC-1α, NRF1, and TFAM, which are linked to mitochondrial regeneration, were found to be significantly reduced (P < 0.05). Additionally, ROS and their activities, as well as the inflammasome NLRP3 and inflammatory factors such as TNF-α, IL-6, and IL-1β, were significantly increased (P < 0.05). These findings suggest that diabetes exacerbates I/R injury in the rat brain by further hindering mitochondrial regeneration, possibly through the SIRT1/SIRT3-PGC-1α-NRF1-TFAM pathway. Additionally, diabetes intensifies this injury by amplifying the inflammatory cascade response, which may be associated with the SIRT1/SIRT3-ROS-NLRP3 pathway.
Indexed as
Identifiers
40580257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.